Invasive breast carcinoma - IARC

References
1 . Anon. (1982). The World Health
Organization Histological Typing of Breast
Tumors-Second Edition. The World Health
Organization. Am J Clin Pathol 78: 806-816.
2. Anon. (1987). The reduction in risk of
ovarian cancer associated with oral-contraceptive
use. The Cancer and Steroid
Hormone Study of the Centers for Disease
Control and the National Institute of Child
Health and Human Development. N Engl J
Med 316: 650-655.
3. Anon. (1990). Surgical-procedure terminology
for the vulva and vagina. Report of
an International Society for the Study of
Vulvar Disease Task Force. J Reprod Med
35: 1033-1034.
4. Anon. (1992). Systemic treatment of early
breast cancer by hormonal, cytotoxic, or
immune therapy. 133 randomised trials
involving 31,000 recurrences and 24,000
deaths among 75,000 women. Early Breast
Cancer Trialists' Collaborative Group.
Lancet 339: 1-15.
5. Anon. (1996). Clinical practice guidelines
for the use of tumor markers in breast and
colorectal cancer. Adopted on May 17,
1996 by the American Society of Clinical
Oncology. J Clin Oncol 14: 2843-2877.
6. Anon. (1997). Consensus conference on
the classification of ductal carcinoma in
situ. Hum Pathol 28: 1221-1225.
7. Anon. (1997). Consensus Conference on
the classification of ductal carcinoma in
situ. The Consensus Conference
Committee. Cancer 80: 1798-1802.
8 . Anon. (1997). Pathology of familial
breast cancer: differences between breast
cancers in carriers of BRCA1 or BRCA2
mutations and sporadic cases. Breast
Cancer Linkage Consortium. Lancet 349:
1505-1510.
9. Anon. (1998). 1997 update of recommendations
for the use of tumor markers in
breast and colorectal cancer. Adopted on
November 7, 1997 by the American Society
of Clinical Oncology. J Clin Oncol 16: 793-
795.
10. Anon. (1998). Tamoxifen for early breast
cancer: an overview of the randomised trials.
Early Breast Cancer Trialists'
Collaborative Group. Lancet 351: 1451-
1467.
11. Anon. (1999). Cancer risks in BRCA2
mutation carriers. The Breast Cancer
Linkage Consortium. J Natl Cancer Inst 91:
1310-1316.
1 2 .Aaltonen LA, Salovaara R, Kristo P, Canzian
F, Hemminki A, Peltomaki P, Chadwick RB,
Kaariainen H, Eskelinen M, Jarvinen H,
Mecklin JP, de la CA (1998). Incidence of
hereditary nonpolyposis colorectal cancer and
the feasibility of molecular screening for the
disease. N Engl J Med 338: 1481-1487.
13. Aarnio M, Mecklin JP, Aaltonen LA,
Nystrom-Lahti M, Jarvinen HJ (1995). Lifetime
risk of different cancers in hereditary
non-polyposis colorectal cancer (HNPCC)
syndrome. Int J Cancer 64: 430-433.
1 4 . Aarnio M, Sankila R, Pukkala E,
Salovaara R, Aaltonen LA, de la CA,
Peltomaki P, Mecklin JP, Jarvinen HJ
(1999). Cancer risk in mutation carriers of
DNA-mismatch-repair genes. Int J Cancer
81: 214-218.
15. Aaro CA, Jacobson LJ, Soule EH (1963).
Endocervical polyps. Obstet Gynecol 21:
659-665.
16. Aas T, Borresen AL, Geisler S, Smith-
Sorensen B, Johnsen H, Varhaug JE,
Akslen LA, Lonning PE (1996). Specific P53
mutations are associated with de novo
resistance to doxorubicin in breast cancer
patients. Nat Med 2: 811-814.
1 7 . Abati AD, Kimmel M, Rosen PP (1990).
Apocrine mammary carcinoma. A clinicopathologic
study of 72 cases. Am J Clin
Pathol 94: 371-377.
18. Abbondanzo SL, Seidman JD, Lefkowitz
M, Tavassoli FA, Krishnan J (1996). Primary
diffuse large B-cell lymphoma of the
breast. A clinicopathologic study of 31
cases. Pathol Res Pract 192: 37-43.
19. Abbott TM, Hermann WJJr., Scully RE
(1984). Ovarian fetiform teratoma
(homunculus) in a 9-year-old girl. Int J
Gynecol Pathol 2: 392-402.
20. Abdul-Karim FW, Bazi TM, Sorensen K,
Nasr MF (1987). Sarcoma of the uterine
cervix: clinicopathologic findings in three
cases. Gynecol Oncol 26: 103-111.
21. Abeler V, Nesland JM (1989). Alveolar
soft-part sarcoma in the uterine cervix.
Arch Pathol Lab Med 113: 1179-1183.
2 2 . Abeler VM, Holm R, Nesland JM,
Kjorstad KE (1994). Small cell carcinoma of
the cervix. A clinicopathologic study of 26
patients. Cancer 73: 672-677.
23. Abeler VM, Kjorstad KE, Nesland JM
(1991). Undifferentiated carcinoma of the
endometrium. A histopathologic and clinical
study of 31 cases. Cancer 68: 98-105.
24. Abeler VM, Vergote IB, Kjorstad KE,
Trope CG (1996). Clear cell carcinoma of
the endometrium. Prognosis and metastatic
pattern. Cancer 78: 1740-1747.
25. Abell MR, Ramirez JA (1973). Sarcomas
and carcinosarcomas of the uterine cervix.
Cancer 31: 1176-1192.
26. Abeln EC, Smit VT, Wessels JW, de
Leeuw WJ, Cornelisse CJ, Fleuren GJ
(1997). Molecular genetic evidence for the
conversion hypothesis of the origin of
malignant mixed mullerian tumours. J
Pathol 183: 424-431.
2 7 . Abner AL, Collins L, Peiro G, Recht A,
Come S, Shulman LN, Silver B, Nixon A, Harris
JR, Schnitt SJ, Connolly JL (1998). Correlation
of tumor size and axillary lymph node involvement
with prognosis in patients with T1 breast
c a r c i n o m a .Cancer 83: 2502-2508.
28. Aboumrad MH, Horn RC, Fine G (1963).
Lipid-secreting mammary carcinoma.
Cancer 16: 521-525.
29. Abrams J, Talcott J, Corson JM (1989).
Pulmonary metastases in patients with
low-grade endometrial stromal sarcoma.
Clinicopathologic findings with immunohistochemical
characterization. Am J Surg
Pathol 13: 133-140.
30. Acharya S, Wilson T, Gradia S, Kane
MF, Guerrette S, Marsischky GT, Kolodner
R, Fishel R (1996). hMSH2 forms specific
mispair-binding complexes with hMSH3
and hMSH6. Proc Natl Acad Sci USA 93:
13629-13634.
3 1 . Ackerman AB, Mihara I (1985).
Dysplasia, dysplastic melanocytes, dysplastic
nevi, the dysplastic nevus syndrome,
and the relation between dysplastic
nevi and malignant melanomas. Hum
Pathol 16: 87-91.
32. Ackerman LV, Katzenstein AL (1977).
The concept of minimal breast cancer and
the pathologist's role in the diagnosis of
"early carcinoma". Cancer 39: 2755-2763.
33. Acosta-Sison H (1970). Chorioadenoma
destruens. A report of 41 case. Am J
Obstet Gynecol 80: 176.
34. Acs G, Lawton TJ, Rebbeck TR, LiVolsi
VA, Zhang PJ (2001). Differential expression
of E-cadherin in lobular and ductal
neoplasms of the breast and its biologic
and diagnostic implications. Am J Clin
Pathol 115: 85-98.
3 5 . Adami HO, Bergstrom R, Hansen J
(1985). Age at first primary as a determinant
of the incidence of bilateral breast
cancer. Cumulative and relative risks in a
population-based case-control study.
Cancer 55: 643-647.
36. Adami HO, Signorello LB, Trichopoulos
D (1998). Towards an understanding of
breast cancer etiology. Semin Cancer Biol
8: 255-262.
37. Adami HO, Sparen P, Bergstrom R,
Holmberg L, Krusemo UB, Ponten J (1989).
Increasing survival trend after cancer
diagnosis in Sweden: 1960-1984. J Natl
Cancer Inst 81: 1640-1647.
38. Adashi EY, Rosenshein NB, Parmley TH,
Woodruff JD (1980). Histogenesis of the
broad ligament adrenal rest. Int J
Gynaecol Obstet 18: 102-104.
39. Adeniji KA, Adelusola KA, Odesanmi
WO, Fadiran OA (1997). Histopathological
analysis of carcinoma of the male breast in
Ile-Ife, Nigeria. East Afr Med J 74: 455-457.
4 0 . Adeyinka A, Mertens F, Idvall I,
Bondeson L, Ingvar C, Heim S, Mitelman F,
Pandis N (1998). Cytogenetic findings in
invasive breast carcinomas with prognostically
favourable histology: a less complex
karyotypic pattern? Int J Cancer 79: 361-
364.
41. Adnane J, Gaudray P, Dionne CA,
Crumley G, Jaye M, Schlessinger J, Jeanteur
P, Birnbaum D, Theillet C (1991). BEK and
FLG, two receptors to members of the FGF
family, are amplified in subsets of human
breast cancers. Oncogene 6: 659-663.
4 2 . Agathanggelou A, Honorio S,
Macartney DP, Martinez A, Dallol A, Rader
J, Fullwood P, Chauhan A, Walker R, Shaw
JA, Hosoe S, Lerman MI, Minna JD, Maher
ER, Latif F (2001). Methylation associated
inactivation of RASSF1A from region
3p21.3 in lung, breast and ovarian tumours.
Oncogene 20: 1509-1518.
4 3 . Agnarsson BA, Jonasson JG,
Bjornsdottir IB, Barkardottir RB, Egilsson
V, Sigurdsson H (1998). Inherited BRCA2
mutation associated with high grade
breast cancer. Breast Cancer Res Treat 47:
121-127.
44. Agoff SN, Grieco VS, Garcia R, Gown
AM (2001). Immunohistochemical distinction
of endometrial stromal sarcoma and
cellular leiomyoma. Appl Immunohistochem
Mol Morphol 9: 164-169.
45. Aguirre P, Scully RE, Wolfe HJ, DeLellis
RA (1986). Argyrophil cells in Brenner
tumors: histochemical and immunohistochemical
analysis. Int J Gynecol Pathol 5:
223-234.
46. Aguirre P, Thor AD, Scully RE (1989).
Ovarian small cell carcinoma. Histogenetic
considerations based on immunohistochemical
and other findings. Am J Clin
Pathol 92: 140-149.
47. Ahern JK, Allen NH (1978). Cervical
hemangioma: a case report and review of
the literature. J Reprod Med 21: 228-231.
48. Ahmed AA, Swan RW, Owen A, Kraus
FT, Patrick F (1997). Uterus-like mass arising
in the broad ligament: a metaplasia or
mullerian duct anomaly? Int J Gynecol
Pathol 16: 279-281.
49. Aho M, Vesterinen E, Meyer B, Purola
E, Paavonen J (1991). Natural history of
vaginal intraepithelial neoplasia. Cancer
68: 195-197.
50. Aida H, Takakuwa K, Nagata H, Tsuneki
I, Takano M, Tsuji S, Takahashi T, Sonoda
T, Hatae M, Takahashi K, Hasegawa K,
Mizunuma H, Toyoda N, Kamata H, Torii Y,
Saito N, Tanaka K, Yakushiji M, Araki T,
Tanaka K (1998). Clinical features of ovarian
cancer in Japanese women with germline
mutations of BRCA1. Clin Cancer Res
4: 235-240.
5 1 . AJCC (2002). AJCC Cancer Staging
Manual. Sixth ed. Springer Verlag: New
York.
372 References